Foreign-invested pharmaceutical firms suffer less damage from price cutbacks of drugs

The government is likely to attempt a smaller-than-expected price reduction on main drugs produced by the 22 multinational pharmaceutical firms, while some foreign-invested firms will suffer substantial damage, according to pharmaceutical business sources. Details:

Individual number of drugs subject to envisaged price reduction

(Unit: In billion won)